Waystar Holding Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a WAY research report →
Range $28 – $39
Price Chart
About the company
Waystar Holding Corp. is dedicated to developing a cloud-based software platform designed to streamline financial transactions within the healthcare industry. Their comprehensive system offers a suite of functionalities, including pre-approving finances, supporting patients with billing, overseeing claims and payments, actively preventing and recovering denied claims, enhancing revenue capture, and providing insightful analytics and reporting.
- CEO
- Matthew J. Hawkins
- IPO
- 2024
- Employees
- 1,700
- HQ
- Lehi, UT, US
Get TickerSpark's AI analysis on WAY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.10B
- P/E
- 38.70
- Fwd P/E
- 15.68
- PEG
- 5.03
- P/S
- 4.13
- P/B
- 1.29
- EV/EBITDA
- 15.08
- Div Yield
- 0.00%
- Gross Margin
- 69.39%
- Op Margin
- 21.92%
- Net Margin
- 10.70%
- ROE
- 3.41%
- ROIC
- 3.38%
Latest fiscal year · YoY change
- Revenue
- $1.10B+16.5%
- Gross Profit
- $751.12M+19.6%
- Op Income
- $249.31M
- Net Income
- $112.09M+686.1%
- EPS
- $0.63+584.6%
- OCF Growth
- +82.4%
- FCF Growth
- +98.7%
- 52W High
- $37.51
- 52W Low
- $17.26
- 50D MA
- $27.09
- 200D MA
- $23.91
- Beta
- 0.07
- RSI (14)
- 40
- Avg Volume
- 2.09M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Waystar posted another strong quarter with 21% revenue growth and 24% EBITDA growth, but it lowered near-term revenue expectations because larger, broader implementations and Iodine mix are taking longer to convert into recognized revenue.· November 2, 2026
- Revenue rose 21% year over year to $326 million; organic revenue grew 10%.
- Adjusted EBITDA increased 24% to $139 million, with margin at 43%; GAAP net income was $31 million, or $0.16 per diluted share.
- Bookings were strong: year-to-date bookings grew 25% year over year, and the company said the largest new client win in its history came this quarter.
- Waystar raised full-year adjusted EBITDA guidance to $543 million-$549 million, but cut full-year revenue guidance to $1.277 billion-$1.287 billion.
- Management said the core issue is timing: larger platform deals, print-to-digital shifts, and Iodine’s outcome-based pricing are extending revenue conversion, not weakening demand.
Waystar reported third-quarter revenue of $326 million, up 21% year over year; organic revenue grew 10%. Subscription revenue was $181 million, up 34%; volume-based revenue was $143 million, up 8%; provider revenue was $243 million, up 28%; and patient payments revenue was $82 million, up 5%. Adjusted EBITDA was $139 million, up 24%, with a 43% margin. GAAP net income was $31 million, or $0.16 per diluted share; non-GAAP net income was $87.1 million, or $0.44 per diluted share. Cash flow from operations was $104 million, unlevered free cash flow was $115 million, and capital expenditures were $10 million. The company ended with about $277 million of cash and short-term investments and a net leverage ratio of 2.2x. For 2026, Waystar now expects full-year revenue of $1.277 billion to $1.287 billion, implying about $323 million of fourth-quarter revenue and approximately 6% growth in Q4. It raised full-year adjusted EBITDA guidance to $543 million to $549 million, implying about $135 million in Q4 EBITDA and a full-year margin of about 42.5% at the midpoint.
Matt Hawkins said the quarter showed strong commercial momentum across the platform, with larger client wins, broader product adoption, and growing channel reach. He emphasized Waystar’s strategy of becoming a connected end-to-end platform and said the company is making progress on AI and Agentic capabilities aimed at creating an autonomous revenue cycle. His tone was confident, but he was careful to frame the revenue reset as a timing issue tied to longer implementation and revenue ramp cycles for larger deals.
Alpana Wegner highlighted strong operating performance: revenue of $326 million, adjusted EBITDA of $139 million, 43% margin, $104 million of operating cash flow, and $115 million of unlevered free cash flow. She said large client relationships now represent about 75% of revenue, NRR was 108%, and the company ended with approximately $277 million of cash and short-term investments, plus net leverage of 2.2x after repurchasing about $21 million of stock in the quarter. She also said fiscal 2026 capex is expected to be $55 million to $60 million and raised full-year adjusted EBITDA guidance by $6 million at the midpoint, while lowering revenue guidance because of longer conversion times, digital statement mix, and Iodine’s shift to performance-based pricing.
Analysts focused on the gap between strong bookings and softer near-term revenue guidance. Management said bookings are converting into backlog and should support long-term low double-digit revenue growth, but larger deals and longer implementation ramps are delaying recognition. Several questions centered on Iodine: management said most traction is coming from outcome-based pricing for Prebill Anomaly Detection, early adopters are producing results in line with expectations, and the company still sees Iodine as accretive in 2027. Analysts also asked about margins, and management said Q4 will be affected by timing, product mix, and planned investment, but the company remains committed to 40%+ EBITDA margins.
The bull case from this call is that demand remains strong, with bookings up 25% year to date, backlog up more than 50% for larger opportunities, and the largest new client win in company history. Management also pointed to expanding platform adoption, more than 100 new payer connections in 2026, and AI-powered offerings that represented about 43% of Q3 bookings.
The main risk is that revenue conversion is slowing as Waystar signs larger, more complex deals that can take 12 to 18 months to ramp. Management also flagged weaker near-term revenue from the print-to-digital shift and slower recognition from Iodine’s outcome-based model, which together pressured the Q4 outlook and led to lower full-year revenue guidance. There is also execution risk around turning strong bookings, backlog, and AI product demand into recognized revenue on the expected timeline.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 72.7%
- Shares Outstanding
- 192.39M
- Float Shares
- 139.78M
of shares held by institutions
319 13F filers
Buy/sell ratio 0.20. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Eqt Fund Management S.A R.L. | 24.88M | 0 |
| Fmr LLC | 24.32M | ▲ 9.27M |
| Canada Pension Plan Investment Board | 19.03M | 0 |
| Blackrock, Inc. | 17.86M | ▲ 419.78K |
| Bain Capital Investors LLC | 13.24M | 0 |
| Vanguard Group Inc | 12.33M | ▲ 41.06K |
| Advent International, L.P. | 11.06M | 0 |
| Vanguard Portfolio Management LLC | 6.50M | ▼ 130.36K |
| Vanguard Capital Management LLC | 5.23M | ▲ 30.86K |
| Bank Of Montreal /Can/ | 5.00M | ▼ 188.14K |
| State Street Corp | 4.75M | ▲ 174.42K |
| Price T Rowe Associates Inc | 3.53M | ▲ 587.42K |
Held by 391 ETFs
Biggest fund positions in WAY by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | Khanna Amit | other | 10,245 |
| Nov 10, 26 | Hawkins Matthew J. | other | 82,500 |
| Nov 10, 26 | Hawkins Matthew J. | sell | 82,500 |
| Nov 10, 26 | Hawkins Matthew J. | other | 82,500 |
| Nov 3, 26 | Bridge T. Craig | other | 12,022 |
| Nov 3, 26 | PACKER GREGORY R | other | 13,413 |
| Nov 3, 26 | Woods Todd Charles | other | 4,042 |
| Oct 23, 26 | Wegner Alpana | other | 3,409 |
| Oct 6, 26 | Hawkins Matthew J. | other | 82,500 |
| Oct 6, 26 | Hawkins Matthew J. | sell | 82,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our WAY coverage
Recent articles, reports, and earnings notes.
Want a deeper read on WAY?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
West Virginia University Health System Selects Waystar's AI-Powered Platform to Transform End-to-End Revenue Cycle Operations
prnewswire.com · Nov 19
Diamond Hill Mid Cap Strategy Q3 2026 Portfolio Review
seekingalpha.com · Nov 18
ARGA Investment Management LP Purchases 64,377 Shares of Waystar Holding Corp. $WAY
defenseworld.net · Nov 4
Waystar Holding Corp. (WAY) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 2
What Waystar (WAY) Said on Its Q3 Earnings Call
marketbeat.com · Nov 2
Waystar (WAY) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com · Nov 2
Waystar Holding (WAY) Beats Q3 Earnings and Revenue Estimates
zacks.com · Nov 2
Waystar Reports Third Quarter 2026 Results
prnewswire.com · Nov 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
